Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.

Blood·2025
Same author

Genotyping from targeted NGS data based on a small set of SNPs correctly matches patient samples.

BMC research notes·2025
Same author

NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.

Leukemia·2025
Same author

Correlation between the tibial plateau angle and occurrence of medial meniscal tears in dogs with complete cranial cruciate ligament rupture.

BMC veterinary research·2025
Same author

repDilPCR: a tool for automated analysis of qPCR assays by the dilution-replicate method.

BMC bioinformatics·2024
Same author

The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL.

Leukemia & lymphoma·2024

Related Experiment Video

Updated: Jun 1, 2026

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Immune modulatory agents in hematopoietic malignancies.

Irina Idler1, Nupur Bhattacharya, Hartmut Döhner

  • 1Innere Medizin III, Uniklinik Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

Cancer Treatment Reviews
|June 8, 2011
PubMed
Summary

Immune modulatory drugs effectively treat multiple myeloma (MM), myelodysplastic syndromes (MDS), and chronic lymphocytic leukemia (CLL). This study explores their clinical impact, mode of action, and effects on the tumor microenvironment and immune response.

Related Experiment Videos

Last Updated: Jun 1, 2026

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Immune modulatory drugs are established treatments for multiple myeloma (MM), del5q myelodysplastic syndromes (MDS), and chronic lymphocytic leukemia (CLL).
  • These drugs are utilized in first-line therapies, often in combination, and also show efficacy in refractory disease settings.
  • The precise mechanisms of action for these important therapeutic agents remain incompletely understood.

Purpose of the Study:

  • To elucidate the clinical impact of immune modulatory drugs across MM, del5q MDS, and CLL.
  • To discuss the intracellular targets and molecular pathways influenced by these compounds.
  • To investigate the phenotypic alterations in the tumor microenvironment and immune modulation induced by these drugs.

Main Methods:

  • Review of clinical data on the efficacy of immune modulatory drugs in MM, del5q MDS, and CLL.
  • Analysis of existing literature on the intracellular targets and mechanisms of action.
  • Examination of studies detailing phenotypic changes in the tumor microenvironment and immune responses.

Main Results:

  • Immune modulatory drugs demonstrate significant clinical benefits in MM, del5q MDS, and CLL, both in initial and refractory cases.
  • These drugs engage specific intracellular targets, leading to downstream effects on cellular pathways.
  • Key phenotypic changes occur within the tumor microenvironment, including modulation of immune cell populations and functions.

Conclusions:

  • Immune modulatory drugs are vital therapeutics for hematologic malignancies, with broad clinical applications.
  • Understanding their intracellular targets and effects on the tumor microenvironment is crucial for optimizing treatment strategies.
  • Further research into their immunomodulatory effects may reveal novel therapeutic approaches.